What is the difference between Retatrutide and Survodutide?

Retatrutide is classified as: Triple agonist of the GIP, GLP-1, and glucagon receptors (investigational incretin/metabolic peptide). Survodutide is classified as: Dual agonist of the glucagon-like peptide-1 (GLP-1) and glucagon receptors (investigational metabolic peptide). Retatrutide is investigational and is not an approved medicine. Survodutide is investigational and is not an approved medicine.

Is Retatrutide or Survodutide approved?

Retatrutide is investigational and is not an approved medicine. Survodutide is investigational and is not an approved medicine. Regulatory status by region is set out in the table above.

How much clinical trial evidence is tracked for Retatrutide and Survodutide?

Peptide Science Daily tracks 34 registered clinical trials for Retatrutide (evidence grade B) and 31 for Survodutide (evidence grade B).

Compound comparison

Retatrutide vs Survodutide

This page sets Retatrutide and Survodutide side by side using the data recorded on Peptide Science Daily: drug class, mechanism of action, regulatory status by region, the evidence grade assigned here, and the number of clinical trials tracked. It is a neutral, factual comparison and does not rank either compound or recommend one over the other.

Side-by-side comparison

Class: Retatrutide
Triple agonist of the GIP, GLP-1, and glucagon receptors (investigational incretin/metabolic peptide)
Survodutide
Dual agonist of the glucagon-like peptide-1 (GLP-1) and glucagon receptors (investigational metabolic peptide)
Mechanism: Retatrutide
In plain terms, retatrutide mimics several natural gut and pancreatic hormones at once to reduce appetite and food intake while affecting how the body handles glucose and energy.
Survodutide
In plain terms, survodutide mimics two hormones at once to reduce appetite and influence how the liver and body handle fat and sugar.
United States (FDA): Retatrutide
Investigational; not approved. Phase 3 TRIUMPH program ongoing, with a first positive topline readout (TRIUMPH-4) reported in December 2025.
Survodutide
Investigational; not approved. Being evaluated in a Phase 3 program (SYNCHRONIZE) for obesity, with additional trials in MASH.
European Union (EMA): Retatrutide
Not authorized; investigational, no marketing authorization.
Survodutide
Not authorized; investigational, no marketing authorization.
Australia (TGA): Retatrutide
Not entered on the Australian Register of Therapeutic Goods (ARTG); investigational only and not approved for supply.
Survodutide
Not entered on the Australian Register of Therapeutic Goods (ARTG); investigational only and not approved for supply.
WADA: Retatrutide
Not listed on the WADA Prohibited List. As an investigational incretin-class agent it is not a banned substance; the closely related approved GLP-1 agonists are on WADA's monitoring program rather than prohibited.
Survodutide
Not listed on the WADA Prohibited List. As an investigational incretin-class agent (a GLP-1/glucagon dual agonist) it is not a banned substance.
Evidence grade: Retatrutide
B
Survodutide
B
Tracked clinical trials: Retatrutide
34
Survodutide
31
Full profile: Retatrutide
Retatrutide profile
Survodutide
Survodutide profile

Comparison of Retatrutide and Survodutide by class, mechanism, regulatory status by region, evidence grade, and number of tracked clinical trials.
Attribute	Retatrutide	Survodutide
Class	Triple agonist of the GIP, GLP-1, and glucagon receptors (investigational incretin/metabolic peptide)	Dual agonist of the glucagon-like peptide-1 (GLP-1) and glucagon receptors (investigational metabolic peptide)
Mechanism	In plain terms, retatrutide mimics several natural gut and pancreatic hormones at once to reduce appetite and food intake while affecting how the body handles glucose and energy.	In plain terms, survodutide mimics two hormones at once to reduce appetite and influence how the liver and body handle fat and sugar.
United States (FDA)	Investigational; not approved. Phase 3 TRIUMPH program ongoing, with a first positive topline readout (TRIUMPH-4) reported in December 2025.	Investigational; not approved. Being evaluated in a Phase 3 program (SYNCHRONIZE) for obesity, with additional trials in MASH.
European Union (EMA)	Not authorized; investigational, no marketing authorization.	Not authorized; investigational, no marketing authorization.
Australia (TGA)	Not entered on the Australian Register of Therapeutic Goods (ARTG); investigational only and not approved for supply.	Not entered on the Australian Register of Therapeutic Goods (ARTG); investigational only and not approved for supply.
WADA	Not listed on the WADA Prohibited List. As an investigational incretin-class agent it is not a banned substance; the closely related approved GLP-1 agonists are on WADA's monitoring program rather than prohibited.	Not listed on the WADA Prohibited List. As an investigational incretin-class agent (a GLP-1/glucagon dual agonist) it is not a banned substance.
Evidence grade	B	B
Tracked clinical trials	34	31
Full profile	Retatrutide profile	Survodutide profile

Common questions

What is the difference between Retatrutide and Survodutide?: Retatrutide is classified as: Triple agonist of the GIP, GLP-1, and glucagon receptors (investigational incretin/metabolic peptide). Survodutide is classified as: Dual agonist of the glucagon-like peptide-1 (GLP-1) and glucagon receptors (investigational metabolic peptide). Retatrutide is investigational and is not an approved medicine. Survodutide is investigational and is not an approved medicine.
Is Retatrutide or Survodutide approved?: Retatrutide is investigational and is not an approved medicine. Survodutide is investigational and is not an approved medicine. Regulatory status by region is set out in the table above.
How much clinical trial evidence is tracked for Retatrutide and Survodutide?: Peptide Science Daily tracks 34 registered clinical trials for Retatrutide (evidence grade B) and 31 for Survodutide (evidence grade B).